Can Ritalin be taken with Vyvanse

LisdexamphetamineDrug groupsAmphetamineLisdexamphetamine is an active ingredient from the group of amphetamines for the treatment of attention deficit / hyperactivity disorder ADHD as a second choice drug. It is a prodrug that is continuously biotransformed in the blood to the active metabolite dexamphetamine. Dexamphetamine increases the concentration of neurotransmitters in the synaptic cleft. The capsules are taken once a day in the morning regardless of meals and improve the symptoms. Possible adverse effects include poor appetite, weight loss, diarrhea, dry mouth, nausea, stomach pain, vomiting, anxiety, dizziness, headache, irritability, and insomnia. The medicine can rarely cause serious side effects.

synonymous: lisdexamfetamine, lisdexamphetamine dimesilate, L-lysine-D-amphetamine, NRP-104, LDX, lisdexamfetamini dimesilas, lisdexamphetaminum, lisdexamphetamine dimesylate


Lisdexamphetamine (LDX) was approved in Switzerland in March 2014 in the form of capsules (Elvanse®). It has been available in the USA since 2007 (Vyvanse®).

In contrast to other ADHD drugs, the dosage form is not retarded. The sustained release is achieved with the conversion of the prodrug. Lisdexamphetamine is legally one of the narcotic drugs and is therefore more stringent on prescription.

Structure and properties

Lisdexamphetamine (C.15H25N3O, Mr = 263.8 g / mol) consists of the enantiomerically pure dexamphetamine, which is covalently bound to the amino acid lysine via a peptide bond. It is a prodrug that is continuously enzymatically hydrolyzed in the blood in the erythrocytes to the active ingredient D-amphetamine. Lysine does not contribute to the therapeutic effect. Lisdexamphetamine is available as lisdexamphetamine dimesilate, a white powder that is soluble in water.


Lisdexamfetamine (ATC N06BA12) is effective against the symptoms of ADHD. The mechanism of action is not fully understood. Dexamphetamine inhibits the reuptake of noradrenaline and dopamine into the presynaptic neuron and increases the concentration of monoamines in the synaptic cleft. In addition, it promotes the release of neurotransmitters from the presynapse.

  • As a second choice treatment for attention deficit / hyperactivity disorder ADHD.
  • Binge Eating (first registration in the USA in 2015)

According to the specialist information. The capsules are taken once a day in the morning, regardless of meals. The contents of the capsules can also be used to prepare a drink that can be consumed immediately.


Like other amphetamines, lisdexamphetamine can be abused as a stimulant intoxicant and can be addictive. However, it has a lower potential for abuse because the active ingredient is released continuously and more slowly.


Numerous precautionary measures must be observed during use. The complete information can be found in the information for healthcare professionals.

unwanted effects

Possible adverse effects include poor appetite, weight loss, diarrhea, dry mouth, nausea, stomach pain, vomiting, anxiety, dizziness, headache, irritability, and insomnia. The medicine can rarely cause serious side effects such as cardiovascular disease (including sudden cardiac death), high blood pressure, psychiatric disorders and convulsions.

see also

ADHD, dexamphetamine, methylphenidate

  • Pharmaceutical product information (CH, USA)
  • Blick S.K., Keating G.M. Lisdexamfetamine. Pediatr Drugs, 2007, 9 (2), 129-35 Pubmed
  • Dew R.E., Kollins S.H. Lisdexamfetamine dimesylate: a new option in stimulant treatment for ADHD. Expert Opin Pharmacother, 2010, 11 (17), 2907-13 Pubmed
  • Hutson P.H., Pennick M., Secker R. Preclinical pharmacokinetics, pharmacology and toxicology of lisdexamfetamine: A novel d-amphetamine pro-drug. Neuropharmacology, 2014 Pubmed
  • Mattingly G. Lisdexamfetamine dimesylate: a prodrug stimulant for the treatment of ADHD in children and adults. CNS Spectr, 2010, 15 (5), 315-25 Pubmed
  • Najib J. The efficacy and safety profile of lisdexamfetamine dimesylate, a prodrug of d-amphetamine, for the treatment of attention-deficit / hyperactivity disorder in children and adults. Clin Ther, 2009, 31 (1), 142-76 Pubmed
  • Steer C., Froelich J., Soutullo C.A., Johnson M., Shaw M. Lisdexamfetamine dimesylate: a new therapeutic option for attention-deficit hyperactivity disorder. CNS Drugs, 2012, 26 (8), 691-705 Pubmed
  • (Manufacturer)

Conflicts of Interest: None / Independent. The author has no relationships with the manufacturers and is not involved in the sale of the products mentioned.

additional Information
Support PharmaWiki with a donation!

© PharmaWiki 2007-2021 - PharmaWiki provides independent and reliable information about medication and health.
This article was last changed on March 23rd, 2020.
Imprint and data protection declaration
Show products for this page